Erika Söderberg Johnsson will take up the position as Chief Financial Officer effective from 20 November 2023.

Erika Söderberg Johnsson comes with broad financial, strategy and operational experience from more than 20 years of CFO experience in multiple life science companies (Biotage AB, Karo Bio AB, Affibody AB and Global Genomics AB) and, most recently, as Senior Advisor in the investment company Kinnevik AB.

“I am delighted that Erika has agreed to join the foundation as our new Chief Financial Officer. Erika comes with a strong background in the life sciences, she is very value-driven and ambitious, and I am confident she will play a key role in our continued development,” says Professor Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, and continues:

“With our annual granting level fast approaching DKK 10 billion and a growing number of large-scale initiatives revolving around national and international partnerships, the complexity of our activities is increasing. Thus, Erika will be heading an area that is expanding and evolving rapidly, and I look forward to working together with her.”

Before she took on her first CFO assignment in 2002, Erika Söderberg Johnsson worked for 10 years in investment banking at SEB. In addition to this, she has extensive board experience from among others Saab AB, Camurus AB, Sectra AB, Mabtech Holding AB, MedCap AB, Lunar Group A/S and Marley Spoon SE AG.

Erika Söderberg Johnsson says: “I am very pleased to have been appointed CFO of the Novo Nordisk Foundation, which in recent years has gained a reputation as one of the world’s leading enterprise foundations supporting research and innovation. I look forward to being able to leverage my expertise and contribute to the foundation’s important task of improving people’s health and the sustainability of society and the planet.”

Erika Söderberg Johnsson holds a MSc In Business and Economics from Stockholm School of Economics.